VIDEO: Black patients with prostate cancer have lowest rate of secondary treatment
CHICAGO — In this Healio video exclusive, Stephen J. Freedland, MD, discusses the racial differences regarding treatment escalation after androgen deprivation therapy in patients with prostate cancer.
Freedland, urologist at Cedars-Sinai Medical Center and Durham VA Medical Center, spoke about the research by Nadine Adriana Friedrich, MD, and colleagues, presented at the ASCO Annual Meeting. This study found that non-Hispanic Black patients had a significantly lower rate of treatment escalation, according to researchers.
“Relative to non-Hispanic white patients, we saw lower rates of needing secondary treatment for all races. In particular, Black men have the lowest rate of needing secondary treatment,” said Freedland.
In this retrospective population-level analysis, researchers identified 164,477 patients diagnosed with prostate cancer and treated with ADT alone from the Veterans Affairs Health Care System. The primary outcome was time from ADT to treatment escalation, defined as receipt of novel hormonal therapy, nonsteroidal antiandrogen therapy or chemotherapy.
“If you don’t get a secondary treatment, you either didn’t need it, or concerningly, you needed it and didn’t get it. The fact that we’re seeing all of these races at lower rates of secondary treatments [...] leads us to be concerned that these other races are being undertreated when they do progress,” said Freedland.
Hispanic patients and patients of other races had similar rates of treatment escalation compared with non-Hispanic white patients, with 5-year Kaplan-Meier estimates of 81 (80.3-81.7%) and 81 (80-82%) for Hispanic patients and other races, respectively, according to researchers.
Reference :
- Friedrich N, et al. Abstract 5078. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Read more about